QUALITATIVE CONSISTENCY OF TREATMENT EFFECTS IN MULTIREGIONAL CLINICAL TRIALS

被引:6
|
作者
Tanaka, Yoko [1 ]
Li, Gang [2 ]
Wang, Yining [3 ]
Chen, Josh [4 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] LifeScan Inc, W Chester, PA USA
[3] Johnson & Johnson, Titusville, NJ USA
[4] Merck & Co Inc, Rahway, NJ 07065 USA
关键词
False-positive; Multiregional clinical trial; Multivariate likelihood ratio test; Probability for claiming consistency; Qualitative consistency; SAMPLE-SIZE; REGIONS; POINTS; DESIGN;
D O I
10.1080/10543406.2012.703603
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Consistency of treatment effects across different regions in multiregional clinical trials (MRCTs) has been an important question for the regulatory authorities. Many consistency definitions are proposed in literature. One of the definitions of consistency is expressed as qualitative consistency, whereas inconsistency is defined as qualitative treatment by region interaction. This article focuses on the qualitative consistency and extends Gail-Simon and Sasabuchi's one-sided multivariate likelihood ratio tests. Simulations are used to evaluate operating characteristics of these qualitative consistency assessment approaches. For a given number of regions, the guideline for setting significance level, and consistency cut-off are explored.
引用
收藏
页码:988 / 1000
页数:13
相关论文
共 50 条
  • [21] Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes
    Chiang, Chieh
    Hsiao, Chin-Fu
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2019, 28 (07) : 2179 - 2195
  • [22] Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials
    Quan, Hui
    Li, Mingyu
    Shih, Weichung Joe
    Ouyang, Soo Peter
    Chen, Joshua
    Zhang, Ji
    Zhao, Peng-Liang
    STATISTICS IN MEDICINE, 2013, 32 (10) : 1691 - 1706
  • [23] Use of likelihood estimates for variances for the design and evaluation of multiregional clinical trials with heterogeneous variances
    Wu, Yuh-Jenn
    Cheng, Yu-Chieh
    Chiang, Chieh
    Cheng, Li-Hsueh
    Liu, Ching-Ti
    Hsiao, Chin-Fu
    STATISTICS IN MEDICINE, 2022, 41 (01) : 87 - 107
  • [24] An Analysis of Japanese Patients Enrolled in Multiregional Clinical Trials in Oncology
    Akihiro Hirakawa
    Fumie Kinoshita
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 207 - 211
  • [25] Strategic inclusion of regions in multiregional clinical trials
    Song, Seung Yeon
    Chee, Deborah
    Kim, EunYoung
    CLINICAL TRIALS, 2019, 16 (01) : 98 - 105
  • [26] Unified additional requirement in consideration of regional approval for multiregional clinical trials
    Teng, Zhaoyang
    Chen, Yeh-Fong
    Chang, Mark
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (06) : 903 - 917
  • [27] Impact of Different Regulatory Requirements for Trial Endpoints in Multiregional Clinical Trials
    Girman, Cynthia J.
    Ibia, Ekopimo
    Menjoge, Shailendra
    Mak, Carmen
    Chen, Joshua
    Agarwal, Anupum
    Binkowitz, Bruce
    DRUG INFORMATION JOURNAL, 2011, 45 (05): : 587 - 594
  • [28] Multiregional Clinical Trials: An Introduction from an Industry Perspective
    Bruce Binkowitz
    Ekopimo Ibia
    Drug information journal : DIJ / Drug Information Association, 2011, 45 : 569 - 573
  • [29] Multiregional Clinical Trials: An Introduction From an Industry Perspective
    Binkowitz, Bruce
    Ibia, Ekopimo
    DRUG INFORMATION JOURNAL, 2011, 45 (05): : 569 - 573
  • [30] Control of Frequentist type I error rates in hierarchical linear models for multiregional clinical trials using a Bayesian method
    Kim, Jeewuan
    Kang, Seung-Ho
    Jin, Ick Hoon
    Park, Junhui
    COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2024,